Effects of atorvastatin on calcium-regulating proteins: A possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats

Basic Research in Cardiology

Volumn 104, Issue 3, 2009, Pages 258-268

  Yao, Lei ^a   Chen, Guo Ping ^a   Lu, Xian ^b   Zheng, Liang Rong ^a   Mou, Yun ^a   Hu, Shen Jiang ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Immunology Division   (China)

Author keywords

Atorvastatin; Cardiacdys function; Phospholamban; Sarcoplasmic reticulum Ca2+ ATPase; Spontaneously hypertensive rat

Indexed keywords

AMLODIPINE; ATORVASTATIN; PHOSPHOLAMBAN; PLACEBO; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GENE EXPRESSION; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HISTOPATHOLOGY; HYPERTENSION; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SPONTANEOUSLY HYPERTENSIVE RAT;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEART; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; PYRROLES; RATS; RATS, INBRED SHR; RATS, WISTAR; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VENTRICULAR FUNCTION, LEFT;

EID: 64949119985     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-008-0751-y     Document Type: Article

References (40)

1. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M (1993) Alterations in sarcoplasmic reticulum gene expression in human failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72:463-469
2. Bauersachs J, Hiss K, Fraccarollo D, Laufs U, Ruetten H (2006) Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects. Cardiovasc Res 72:438-446
3. Black AE, Sinz MW, Hayes RN, Woolf TF (1998) Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylgutaryl-coa reductase inhibitor atorvastatin. Drug Metab Dispos 26:755-763
4. Boknik P, Heinroth-Hoffmann I, Kirchhefer U, Knapp J, Linck B, Luss H, Muller T, Schmitz W, Brodde O, Neumann J (2001) Enhanced protein phosphorylation in hypertensive hypertrophy. Cardiovasc Res 51:717-728
5. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD (2004) PKC-α regulates cardiac contractility and propensity toward heart failure. Nat Med 10:248-254
6. Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG (2002) Type 1 phosphatase, a negative regulator of cardiac function. Moll Cell Biol 22:4124-4135
7. Collins HL, Loka AM, Dicarlo SE (2004) Daily exercise-induced cardioprotection is associated with changes in calcium regulatory proteins in hypertensive rats. Am J Physiol Heart Circ Physiol 288:532-540
8. Del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK, Lewandowski ED, Hajjar RJ (2001) Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 104:1424-1429
9. Gupta RC, Mishra S, Rastogi S, Imai M, Habib O, Sabbah HN (2003) Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 285:H2373-H2381
10. Haghighi K, Gregory KN, Kranias EG (2004) Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun 322:1214-1222
11. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ, Kemp BE, Venema RC (2004) Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287:H560-H566
12. Hasenfuss G, Pieske B (2002) Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34:951-969
13. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A (2002) Fluvastatin, a 3-Hydroxy-3-Methylglutaryl coenzyme A reductase inhibitor, attenuate left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105:868-873
14. Jones LR, Besch HR, Fleming JW, McConnaughey MM, Watanabe AM (1979) Separation of vesicles of cardiac sarcolemma from vesicles of cardiac sarcoplasmic reticulum. Comparative biochemical analysis of component activities. J Biol Chem 254:530-539
15. Kokubo M, Uemura A, Matsubara T, Murohara T (2005) Noninvasive evaluation of the time course of change in cardiac function in spontaneously hypertensive rats by echocardiography. Hypertens Res 28:601-609
16. Kubo H, Margulies KB, Piacentino V, Gaughan JP, Houser SR (2001) Patients with end-stage congestive heart failure treated with β-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 104:1012-1018
17. Kubota Y, Umegaki K, Kagota S, Tanaka N, Nakamura K, Kunitomo M, Shinozuka K (2006) Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull 29:1756-1758
18. Lamberts RR, Vaessen RJ, Westerhof N, Stienen GJ (2007) Right ventricular hypertrophy causes impairment of left ventricular diastolic function in the rat. Basic Res Cardiol 102(1):19-27
19. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, Mueller M, Fuchs M, Hornig B, Haller H, Drexler H (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110:1933-1939
20. Maack C, O'Rourke B (2007) Excitation-contraction coupling and mitochondrial energetics. Basic Res Cardiol 102(5):369-392
21. 2+ cycling contributes to improved contractile performance in SERCA2a-overexpressing transgenic rats. Cardiovasc Res 67:636-646
22. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G (1995) Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92:778-784
23. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR (1999). Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99:313-322
24. Mousa SA, Goncharuk O, Miller D (2007) Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure. Expert Opin Biol Ther 7:617-625
25. 2+-ATPase activity and dephosphorylated phospholamban contribute to contractile dysfunction in human hibernating myocardium. Mol Cell Biochem 282:53-63
26. Node K, Fujita M, Kitakaze M, Hori M, Liao JK (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108:839-843
27. Porter MJ, Heidkamp MC, Scully BT, Patel N, Martin JL, Samarel AM (2003) Isoenzyme-selective regulation of SERCA2 gene expression by protein kinase C in neonatal rat ventricular myocytes. Am J Physiol Cell Physiol 285:C39-C47
28. Rejane P, Christophe B, Olicier B et al (2006) Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ Res 98:361-369
29. 2+ responsiveness with training in hypertension. Med Sci Sport Exer 38:847-855
30. Sande JB, Sjaastad I, Hoen IB, Bøkenes J, Tønnessen T, Holt E, Lunde PK, Christensen G (2002) Reduced level of serine (16) phosphorylated phospholamban in the failing rat myocardium: A major contributor to reduced SERCA2 activity. Cardiovasc Res 53:382-391
31. Sevilla MA, Voces F, Carrón R, Guerrero EI, Ardanaz N, San Román L, Arévalo MA, Montero MJ (2004) Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: Persistent effects after withdrawal. Life Sci 75:881-891
32. Simko F, Matuskova J, Luptak I, Krajcirovicova K, Kucharska J, Gvozdjakova A, Babal P, Pechanova O (2004) Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 74:1211-1214
33. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47:332-337
34. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY (2005) Effect of β-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 128:1812-1821
35. Tanaka K, Honda M, Takabatake T (2004) Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin Exp Pharmacol Physiol 31:360-364
36. Weber T, Neumann J, Meissner A, Grosse Hartlage M, Van Aken H, Schmitz W, Boknik P (2006) Reduced serine-16 and threonine-17 phospholamban phosphorylation in stunning of conscious dogs: No evidenced for any involvement of protein kinase A or protein phosphatases. Basic Res Cardiol 101:253-260
37. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Poloński L, Dyrbus K, Badziński A, Mercik G, Zembala M, Wodniecki J, Rozek MM (2006) Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 97:899-904
38. Yasunari K, Maeda K, Minami M, Yoshikawa J (2001) HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 21:937-942
39. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Nishio M, Ohtani T, Miwa T, Hori M, Masuyama T (2004) AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 43:686-691
40. Zheng X, Hu SJ (2005) Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart. Acta Pharmacol Sin 26:696-704